NightstaRX raises $35m series B
Biopharmaceutical company NightstaRX has raised $35m in its series-B funding round, led by New Enterprise Associates (NEA).
Founding investor Syncona, a subsidiary of the Wellcome Trust, also contributed to the round.
Company
NightstaRX's lead programme is a gene therapy for an inherited form of progressive blindness - choroideremia - developed by professor Robert MacLaren at Oxford's Nuffield Laboratory of Ophthalmology. Choroideremia affects around one in 50,000 people.
NightstaRX spun out of Oxford University in 2014 and is focused on the development of therapies for retinal dystrophies.
People
As part of the investment, David Mott, general partner at NEA, has joined the board of NightstaRX. Chris Hollywood, a partner at Syncona, is chair of NightstaRX.
More on UK / Ireland
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater